A236340 Stock Overview
MEDIZEN HUMANCARE Inc., a research company, engages in the genomic analysis to predict diseases on an individual basis in Asia, the Americas, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MEDIZEN HUMANCARE Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,050.00 |
| 52 Week High | ₩6,800.00 |
| 52 Week Low | ₩3,240.00 |
| Beta | 0 |
| 1 Month Change | -6.48% |
| 3 Month Change | 6.32% |
| 1 Year Change | -22.31% |
| 3 Year Change | -45.23% |
| 5 Year Change | -64.69% |
| Change since IPO | -44.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| A236340 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 1.1% | 0.7% | 1.0% |
| 1Y | -22.3% | 1.7% | 8.7% |
Return vs Industry: A236340 underperformed the KR Life Sciences industry which returned 1.7% over the past year.
Return vs Market: A236340 underperformed the KR Market which returned 8.7% over the past year.
Price Volatility
| A236340 volatility | |
|---|---|
| A236340 Average Weekly Movement | 9.1% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A236340's share price has been volatile over the past 3 months.
Volatility Over Time: A236340's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | n/a | www.medizencare.com |
MEDIZEN HUMANCARE Inc., a research company, engages in the genomic analysis to predict diseases on an individual basis in Asia, the Americas, Europe, and internationally. Its services include M-CHECK, which provides an analysis of patients’ risk for genetic diseases using genomic variation packages related to specific diseases with gene chips or analysis kits; and MELTHY (DTC), a DNA analysis service. The company was founded in 2012 and is based in Seoul, South Korea.
MEDIZEN HUMANCARE Inc. Fundamentals Summary
| A236340 fundamental statistics | |
|---|---|
| Market cap | ₩11.64b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A236340 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A236340 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A236340 perform over the long term?
See historical performance and comparison